Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total concentration (1.67 mg/mL each peptide).
Typical daily range: 100–300 mcg of each peptide once daily (gradual titration).
Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 33.3 mcg of each peptide on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Dosing & Reconstitution Guide
Educational guide for reconstitution and weekly dosing
Week | Daily Dose (mcg each) | Units (per injection) (mL) |
Weeks 1–2 | 100 mcg each | 3 units (0.03 mL) |
Weeks 3–4 | 150 mcg each | 4.5 units (0.045 mL) |
Weeks 5–6 | 200 mcg each | 6 units (0.06 mL) |
Weeks 7–12 | 250–300 mcg each | 7.5–9 units (0.075–0.09 mL) |
Frequency: Inject once daily subcutaneously, typically before bed or upon waking. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Reconstitution Steps
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
8 weeks ≈ 3 vials
12 weeks ≈ 4 vials
16 weeks ≈ 5 vials
Per week: 7 syringes (1/day)
8 weeks: 56 syringes
12 weeks: 84 syringes
16 weeks: 112 syringes
Bacteriostatic Water: Use ~3.0 mL per vial for reconstitution.
8 weeks (3 vials): 9 mL
12 weeks (4 vials): 12 mL
16 weeks (5 vials): 15 mL
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
Per week: 14 swabs (2/day)
8 weeks: 112 swabs
12 weeks: 168 swabs
16 weeks: 224 swabs
Protocol Overview
Concise summary of the once-daily regimen.
Goal: Support pulsatile GH release through synergistic GHRH + GHS stimulation.
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Dose Range: 100–300 mcg of each peptide daily with gradual titration.
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Dosing Protocol
Suggested daily titration approach.
Start: 100 mcg each peptide daily; increase by ~50 mcg every 1–2 weeks as tolerated.
Target: 200–300 mcg each peptide daily by Weeks 5–12.
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Timing: Typically before bed or upon waking; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~28 days; avoid freeze–thaw.
Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
Use new sterile insulin syringes; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose and site rotation to maintain consistency.
For doses under 10 units, use 30- or 50-unit syringes for better precision.
How This Works
CJC-1295 (no DAC) is a modified GHRH analog (tetrasubstituted 29-amino acid peptide) that stimulates pulsatile GH release from the pituitary. Human studies demonstrate sustained, dose-dependent increases in both GH and IGF-1 with subcutaneous administration. Ipamorelin is a pentapeptide GH secretagogue with a half-life of approximately 1.5–2.5 hours that elicits a rapid GH pulse peaking around 40 minutes post-dose. Importantly, Ipamorelin selectively increases GH without affecting ACTH, cortisol, or prolactin levels. When combined, these peptides may produce synergistic GH release by acting on complementary receptor pathways.
Potential Benefits & Side Effects
Observations from preclinical and clinical literature.
Supports sustained GH and IGF-1 elevation through pulsatile release patterns.
Ipamorelin demonstrates selective GH release without cortisol or ACTH elevation.
Once-daily dosing of CJC-1295 (no DAC) has been shown to normalize growth in animal models.
Generally well tolerated; possible transient effects may include flushing, headache, or injection-site reactions.
Some individuals report increased appetite, water retention, or tingling sensations.
Lifestyle Factors
Complementary strategies for best outcomes.
Pair with a balanced, protein-forward diet tailored to energy needs.
Combine resistance training and aerobic activity to reinforce metabolic adaptations.
Prioritize sleep quality, as GH is predominantly released during deep sleep.
Manage stress to support optimal hormonal balance and recovery.
Injection Technique
General subcutaneous guidance from clinical best-practice resources.
Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
Do not aspirate for subcutaneous injections; inject slowly and steadily.
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.